Recursion Pharmaceuticals announced a preliminary third quarter 2026 cash balance of approximately $561 million and the pricing of a $200 million underwritten offering. The capital raise, priced at $3.25 per share, is expected to extend the company's operational runway into 2029. Additionally, the company reported updated clinical data for its lead oncology and rare disease programs, alongside a new partnership milestone with Sanofi.
Key Highlights
- Priced a $200 million follow-on offering of 61,540,000 shares to fund pipeline expansion and AI platform development.
- REC-4881 demonstrated a 47% median reduction in total polyp burden in FAP patients, with 85% of patients maintaining reductions below baseline 12 weeks after stopping treatment.
- REC-1245 Phase 1 data showed a 91.7% disease control rate at doses of 45mg or higher, including two confirmed partial responses in endometrial cancer.
- Sanofi optioned its first development candidate from the multi-program collaboration, triggering a $10 million milestone payment to Recursion.